Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib and Sintilimab with Electroacupuncture in MSS Advanced Colorectal Cancer
NCT06456515Phase 2Recruiting
- Sponsor
- Changzhou First People's Hospital
- Start
- May 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib, sintilimab in colorectal cancer (metastatic) (mCRC), sponsored by Changzhou First People's Hospital. Started May 2024; status: recruiting.
02
Drugs
regorafenibsintilimab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT06456515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06456515.